Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia

Ezrin's role in gastric cancer progression: Implications for immune microenvironment modulation and therapeutic potential

“…Studies by Orian-Rousseau et al demonstrated that CD44v6 and Ezrin activate the ERK signal transduction pathway through their interaction, indicating a connection between Ezrin and this pathway [ 32 ]. This suggests that the Ezrin protein may be involved in various cell activities, including proliferation, migration, and apoptosis, through the ERK and Akt signaling pathways [ [33] , [34] , [35] ]. Ezrin is closely associated with molecules that regulate PI3K, AKT, Erk1/2, MAPK, and Rho pathways, which are crucial in controlling cell survival and migration signals [ 36 ].…”

Perspectives for Targeting Ezrin in Cancer Development and Progression

“…In a comprehensive analysis of cytoskeleton regulatory genes, Lipreri da Silva et al [55] identified that high EZR expression is an independent marker of worse outcomes in acute myeloid leukemia patients, and EZR pharmacological inhibition reduced viability, proliferation, autonomous clonal growth, and cell cycle progression in leukemia cells. In chronic lymphocytic leukemia (CLL), EZR is highly expressed and associated with molecular signatures relevant to the disease's development and maintenance, including TP53, PI3K/AKT/mTOR, NFκB, and MAPK pathways [56]. Pharmacological EZR inhibition with NSC305787 reduced viability, clonogenicity, and cell cycle progression and induced apoptosis in CLL primary and cell lines [56].…”

“…In chronic lymphocytic leukemia (CLL), EZR is highly expressed and associated with molecular signatures relevant to the disease's development and maintenance, including TP53, PI3K/AKT/mTOR, NFκB, and MAPK pathways [56]. Pharmacological EZR inhibition with NSC305787 reduced viability, clonogenicity, and cell cycle progression and induced apoptosis in CLL primary and cell lines [56].…”